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Niemann-Pick C1-Like 1 (NPC1-L1), as its name indicates, was identified in 2000 as a 
homolog of NPC1.  Its major physiological function was clarified by a research group in 
Shöring’s laboratory who had long been searching for a target of ezetimibe, a cholesterol-
lowering drug.  They published a paper on 2004 in Science, reporting a reduction of intes-
tinal cholesterol absorption and a lack of effects of ezetimibe in NPC1-L1 knockout mice. 
With subsequent studies that confirmed their findings, it is now clear that NPC1-L1 is a 
key player in one of the major pathways of intestinal cholesterol absorption and that it is 
the target of ezetimibe.  This review summarizes what has been shown up to now about the 
structure and function of NPC1-L1.  This review also refers to ABCG5/G8, a member of 
ABC family transporters, which co-localizes with NPC1-L1 on the intestinal epithelial cells 
and appears to work in a closely related manner.
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Structures of NPC1 and NPC1-L1
Let us start with Niemann-Pick disease type C1 
(NPC1) which was identified on 1997 (Fig. 1), be-
cause it is the prototype of these two proteins and 
hence much of what we know about NPC1-Like 1 
(NPC1-L1) originates in studies on NPC1.  It is a 
glycoprotein with a molecular mass of 170 to 200 
kDa and is predicted to contain 13 transmembrane 
domains.  Its primary structure is featured by a sig-
nal peptide on its N-terminus and a dileucine motif 
on the C-terminus, the latter of which is believed to 
be a targeting signal to the endosome (Davies et al., 
2000).  The N-terminal extracellular loop contains 
an amino acid sequence of approximately 100 ami-
no acids long (55–165), which is of high conserva-
tion between species, and is called an Niemann-
Pick disease type C (NPC) domain.  Recent studies 
have shown that cholesterol directly binds to this 
domain (Infante et al., 2008).  The middle part of 
this molecule (transmembrane domain 5–8) consti-
tutes a sterol-sensing domain (SSD).  The SSD is 
shared by other molecules involved in the control 
of cholesterol homeostasis, including hydroxy-
methyl-glutaryl-CoA reductase and sterol regula-
tory element-binding protein cleavage-activating 
protein.  NPC1 is one of the house-keeping genes, 
expressed in every tissue and cell. 
 Loss of function of NPC1 results in NPC, an 
autosomal recessive lipid storage disease (Patterson 
et al., 2001).  Although heterogeneous, NPC is typi-
cally a childhood disease with an onset in the in-
fancy and an eventual demise in the second decade 
of life.  The NPC kids exhibit a variety of neuro-
logical symptoms including ataxia, cataplexy, verti-
cal gaze palsy and so on.  At the cellular level, the 
most prominent feature of NPC is accumulation of 
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free cholesterol in the endosome/lysosome.  Cho-
lesterol is supplied to peripheral cells mainly by 
low-density lipoprotein (LDL).  Lysosomal hydo-
lyses convert cholesterol esters in LDL to the free 
form, which then must be delivered to other cel-
lular compartments such as the plasma membrane 
and the endoplasmic reticulum.  NPC1 localizes 
mainly in the late endosomes.  Cells without NPC1 
function fail to transport cholesterol out of the en-
dosomes and develop hybrid structures containing 
both the marker molecules of late endosomes and 
lysosomes.  These abnormal endosomes contain 
multivesicular bodies within their lumen.  Because 
of these loss-of-function phenotypes, it is clear that 
NPC1 takes part in the cholesterol transport out of 
the endosomal system.  Although the precise mech-
anism of action remains to be clarified, it has been 
shown that the protein “moves” within the cell, be-
ing contained in transport vesicles that shuttle be-
tween cellular compartments (Zhang et al., 2001).
Fig. 1.  Structure and function of NPC1 and NPC1-L1.  See text for details.  NPC, Niemann-Pick disease type C; NPC1, 
Niemann-Pick disease type C1; NPC2, Niemann-Pick disease type C2; NPC1-L1, NPC1-Like 1; SSD, sterol-sensing do-
main.
 NPC1-L1 has the amino acid sequence that is 
40% identical to that of NPC1 and is predicted to 
have a similar secondary structure.  Like NPC1, 
it has a signal peptide on its N-terminus, an NPC 
domain on its N-terminal extracellular loop, and an 
SSD in its middle part.  A clear difference is that it 
lacks the C-terminal dileucine motif (Davies et al., 
2000).  The tissue distribution of NPC1-L1 is also 
quite different from that of NPC1; both in mice and 
humans, its expression is tissue-specific and is spe-
cifically high in the small intestine.  According to 
an analysis in mice, its expression is heterogeneous 
in the intestine, being high in the duodenum and 
jejunum, and low in the ileum (Davis et al., 2004). 
This distribution provides a good explanation for 
the fact that dietary cholesterol is absorbed mainly 
in the duodenum and jejunum.  It should be noted 
that its expression level in the liver is clearly differ-
ent between mice and humans; in humans, its level 
in the liver is as high as in the intestine whereas it 
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Fig. 2.  Cholesterol circulation and NPC1-L1 localization. 
In humans, NPC1-L1 resides on the apical membrane of 
intestinal absorptive cells and in bile canaliculi of hepato-
cytes, where it facilitates cholesterol uptake.  ABCG5/G8 
resides on the same sites and facilitates cholesterol flow in 
the opposite direction.  NPC1-L1, Niemann-Pick disease 
type C1-Like 1.
is barely expressed in mouse livers.  Histochemi-
cal studies using human tissues demonstrated its 
sequestration on the brush border membrane of 
the intestinal epithelial cells and on the bile canali-
culi of hepatocytes (Sané et al., 2006; Temel et al., 
2007).  Figure 2 depicts its cellular localization in a 
scheme.
 Intestinal absorption of dietary cholesterol 
in NPC1-L1 knockout mice is reduced to approxi-
mately half the level of that in wild-type mice 
(Altmann et al., 2004).  Feeding of the knockout 
mice with a high-cholesterol diet failed to induce 
hypercholesterolemia and resultant fatty liver 
(Davies et al., 2005). 
 Its selective tissue distribution and the phe-
notypes of gene knockout mice made it clear that 
NPC1-L1 is required for intestinal absorption of di-
etary cholesterol.  Following studies focused on how 
this protein takes part in the absorption process at 
the molecular level.  Although its localization in the 
hepatic canaliculi suggests its role in cholesterol up-
take from bile, the following discussion focuses on 
its role in the intestine, because of space limitation.
 
 
Intracellular sequestration  
of NPC1-L1 and cholesterol transport:  
findings in cultured cells
Immediately following its identification, the intra-
cellular localization of NPC1-L1 was examined 
using cultured cells and epitope-tagged recombi-
nant proteins.  Initial two reports were obviously 
contradictory to each other.  Shöring’s group re-
ported localization of NPC1-L1 tagged with Flag 
epitope or Green Fluorescent Protein (GFP) on the 
cell surface of Chinese hamster ovary cells (Iyer et 
al., 2005) whereas Mt. Sinai’s group demonstrated 
localization of Yellow Fluorescent Protein-tagged 
NPC1-L1 in the intracellular vesicles of COS cells 
(Davies et al., 2005).  The latter group also showed 
sequestration of endogenous NPC1-L1 in cytosolic 
vesicles of HepG2 cells.  They claimed that these 
vesicles represent early endosomes and recycling 
endosomes that emanate from them. 
 A later report appeared to reconcile the dis-
crepancy of these initial studies.  Yu et al. studied 
intracellular localization of GFP-tagged NPC1-L1 
in rat hepatoma cells and observed that this protein 
shuttles between the cell surface and cytosolic ves-
icles (Yu et al., 2006).  This movement appeared to 
be regulated by the cellular level of cholesterol:  the 
protein resided on the cell surface in a low-cholester-
ol condition and on the cytosolic vesicles in a high-
cholesterol condition.  The cytosolic vesicles ap-
peared to be recycling endosomes because they con-
tained fluorescent transferrin. Subsequently, several 
groups made a similar observation that NPC1-L1 
“moves” within the cell in a cholesterol-dependent 
manner (Ge et al., 2008; Petersen et al., 2008).  Our 
observation using a confocal microscopy is depicted 
in Fig. 3.  It has also been shown that the movement 
from the cell surface to the endosome depends on 
clathrin/AP2 complexes (Ge et al., 2008). 
 This intracellular movement of NPC1-L1 is 
reminiscent of that of NPC1.  In the case of NPC1, 
it has been shown that a steroid-derivative U18666A 
that inhibits its function apparently blocks its in-
tracellular movement.  Likewise, the intracellular 
movement of NPC1-Like1 is blocked by its inhibitor 
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ezetimibe.  These pharmacological findings suggest 
that these proteins must move between the cellular 
compartments to operate cholesterol transport.   
Function of NPC1-L1  
in intestinal epithelial cells
There has been no report yet that examined intrac-
ellular localization of NPC1-L1 in the intestinal ep-
ithelium in situ.  On ordinary immunohistochemi-
cal examinations of fixed tissues, it appears to be 
sequestrated on the apical membrane of absorp-
tive cells; however, immunoelectron microscopy 
revealed that in addition to the apical membrane, 
it was also localized on the limiting membrane 
of intracellular vesicles (Sané et al., 2006).  From 
morphological features, these vesicles appear to be 
lysosomes. 
 The intestinal absorptive cells receive choles-
terol from biliary micelle on its apical membrane 
and package it in chylomicron, which in turn is re-
leased from the basolateral membrane.  Almost all 
of the cholesterol molecules in biliary micelle are 
Fig. 3.  Intracellular localization of Yellow Fluorescent Protein-tagged NPC1-L1 expressed in Human Embryonic Kid-
ney 293 cells.  
A: Low-cholesterol condition.  Cells cultured in lipoprotein-deficient serum were treated with methyl- -cyclodextrin 
to reduce cellular cholesterol contents. 
B: High-cholesterol condition.  Cells in condition A were loaded with free cholesterol. 
NPC1-L1, Niemann-Pick disease type C1-Like 1.  
in the free form whereas they are in the esterified 
form in chylomicron. These conversion and trans-
port processes consist of multiple steps as shown in 
Fig. 4. Depending on the observations in cultured 
cells, the site of action of NPC1-L1 is thought to be 
step 2, in which the cholesterol-enriched plasma 
membrane domains are internalized to the endo-
somal compartment.
 The total cholesterol content of intestinal 
epithelial cells from NPC1-L1 knockout mice was 
reduced compared with wild-type mice, which 
does not contradict the role of this protein in step 
2 (Davies et al., 2005).  Knopfel et al. found no 
difference in the rate of in vitro cholesterol uptake 
between the apical membrane vesicles prepared 
form the wild-type and knockout mice (Knopfel et 
al., 2007).  Accordingly, ezetimibe failed to reduce 
the capacity of these vesicles to take up cholesterol. 
These negative data indicate that step 1 (i.e., trans-
fer of micellar cholesterol to the apical membrane) 
does not depend on NPC1-L1 function. 
 As described above, the cholesterol transport 
out of the endosomal system (steps 3 and 4 in Fig. 
4) depends on NPC1 function and its deficiency 
A B
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 Cholesterol molecules take either free or es-
terified form in our body.  Biochemically, the free 
form possesses both hydrophilic and hydrophobic 
parts and is thus amphiphilic whereas the esteri-
fied form is totally hydrophobic.  Owing to its 
amphiphilic nature, the free form always resides 
within a membrane, i.e., on a two-dimensional 
surface, whereas the esterified can form a three-
dimensional particle. 
 Most of the cholesterol molecules delivered 
to peripheral cells by LDL are in the esterified 
form.  To utilize these molecules for structural or 
metabolic purposes, cells hydrolyze them to the 
free form in the endosomes and lysosomes.  This 
conversion requires a massive amount of mem-
branes, because the molecules tightly packed in a 
three-dimensional particle must be spread to a two-
dimensional membrane.  In the endosomal system, 
this amount of membranes is supplied by multive-
sicular bodies, which form three-dimensional par-
ticles of stratified membranes.  NPC1 is required 
to transport these membrane structures out of the 
endosomal system.
 Cholesterol molecules are delivered to the 
intestinal epithelial cells mostly in their free form, 
because of hydrolysis of dietary cholesterol by di-
gestive enzymes.  These molecules enter the apical 
side of the cells where a massive amount of mem-
branes is equipped by forming microvilli.  NPC1-
L1 is required to transport the membranes from 
here to the endosomal system.  Thus in both cases, 
an elaborate membrane system was prepared to 
deal with free cholesterol.  Both NPC1 and NPC-
L1 work as a chaperon to transport the membranes 
out of these compartments. 
 
 
Cholesterol-specificity of  
NPC1-L1 function
 
Neither the serum concentrations of free fatty acids 
nor lipid-soluble vitamins were altered in NPC1-L1 
knockout mice (Altmann et al., 2004).  When ad-
ministered to healthy humans, ezetimibe reduced 
the serum concentration of LDL but failed to alter 
Fig. 4.  Intracellular cholesterol flow in intestinal absorp-
tive cells.  Free cholesterol (FC) contained in biliary mi-
celle is incorporated into the apical side membrane ( ) and 
then transported to the endosomes ( ).  A part of internal-
ized FC is recycled back to the apical side and is excreted 
by ABCG5/G8 ( ).  Another part is transported to the 
endoplasmic reticulum ( ) where it is esterified and pack-
aged in chylomicron.  FC is also supplied by endogenous 
synthesis from acetylCoA.  Step  depends on Niemann-
Pick disease type C1-Like 1 function while others do not.
leads to endosomal free cholesterol accumulation. 
This is also true for intestinal epithelial cells, as 
evidenced by positive filipin staining of these cells 
from NPC1 knockout mice.  However, the rate of 
intestinal cholesterol absorption was not at all re-
duced in these mice compared with wild-type mice 
(Dixit et al., 2007).  Thus it appears that cholesterol 
molecules derived either from biliary micelle or 
from LDL take different transport pathways in 
these cells. 
 
 
NPC1 and NPC1-L1 as chaperons  
for cholesterol-enriched membranes
 
NPC1 and NPC1-L1 share the amino acid sequenc-
es of no more than 40% identity and they have 
quite different tissue specificity and intracellular 
sites of action.  However, the above-mentioned 
studies have shed light to some common aspects of 
the functions of these two proteins. 
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those of other lipid molecules including triglycer-
ide.  These findings suggested that the function of 
NPC1-L1 was specifically required for the transport 
of cholesterol but not for that of other lipids.  Given 
the role as chaperones for membrane transport, 
however, a speculation persists that NPC1-L1 is in-
volved in the transport of other membrane lipids. 
 Narushima et al., by using an expression 
system in Coca2 cells, found that NPC1-L1 facili-
tated cellular absorption of -tocofenol (vitamin E) 
(Narushima et al., 2008).  Labonte et al. reported 
that in mice, NPC1-L1 facilitated intestinal absorp-
tion of saturated fatty acids, and that its inhibition 
lead to suppression of insulin resistance and weight 
gain (Labonte et al., 2008).  If the latter findings 
are also true for humans, eztimibe may have dream 
effects in prevention of diabetes mellitus and obe-
sity.  It is of regret to note that in humans, there 
has been no report yet of weight loss caused by 
administration of this drug.  In addition, the rate of 
intestinal cholesterol absorption had no relation to 
the body mass index values (Cohen et al., 2006). 
 
 
Co-operation by  
NPC1-L1 and ABCG5/G8
 
ABCG5/G8, a heterodimer of G5 and G8 subunits, 
is a member of the ATP-binding Cassette (ABC) 
transporter family.  Similar to NPC1-L1, this pro-
tein localizes on the apical membrane of intestinal 
absorptive cells, but in quite contrary to NPC1-L1, 
it operates cholesterol transport from the cells to 
the intestinal lumen:  thus NPC1-L1 and ABCG5/
G8 work in an opposite direction in the regulation 
of intestinal cholesterol flow.  In humans, these two 
proteins also co-localize in bile canaliculi.  Loss of 
function of either G5 or G8 proteins results in he-
reditary sitosterolemia characterized by increased 
serum and tissue levels of sterols derived from 
plants. 
 In general, co-operation of two proteins that 
function in an opposite direction to and indepen-
dently from each other enables a regulation in 
a wider range and in a faster speed.  As for the 
range, the net intake of intestinal cholesterol is de-
termined by summation of addition by NPC1-L1 
and subtraction by ABCG5/G8.  As related to the 
speed, NPC1-L1 appears to be the major determi-
nant.  This is because upon cellular loading of cho-
lesterol, NPC1-L1 is internalized within minutes, 
whereas there is no known regulatory mechanism 
for ABCG5/G8 that operates within this time lag. 
 Apart from the efficiency of regulation, the 
set of NPC1-L1 and ABCG5/G8 is implicated in 
selection of sterol species.  Our diet contains sterols 
from both animals and plants, the latter of which 
(plant sterols or phytosterols) cannot be utilized by 
our body.  Although NPC1-L1 facilitates absorp-
tion of phytosterols (Yamanashi et al., 2007), it 
is relatively selective for animal-derived sterols. 
ABCG5/G8 has clear preference to phytosterols. 
Thus for the selective absorption of animal-derived 
sterols, the intestinal cells adopt a dual filtering 
system that preferentially takes in useful molecules 
and discards useless ones.  NPC1-L1 gene knock-
out in ABCG5/G8-deficient mice prevented them 
from developing hyperlipidemia (Tang et al., 2009), 
suggesting that a major portion of phytosterols 
discarded by ABCG5/G8 is taken up by NPC1-L1. 
This is in accordance with the observed effects of 
ezetimbe to suppress symptoms and signs of pa-
tients with hereditary sitosterolemia. 
 
 
Human genetics of NPC1-L1
 
Besides basic studies on cultured cells or experi-
mental animals, studies on humans are in progress. 
One of the major subjects of these studies is the 
genotype-phenotype relationship of NPC1-L1.  The 
efficacy of intestinal cholesterol absorption varies 
between individuals, in a range from as low as 30 
up to 80%.  Given the role of NPC1-L1 as a criti-
cal player in this process, one would expect to see 
whether the genomic variation of this gene could 
explain the individual variation of the absorption 
efficacy.  Studies are going on to analyze this re-
lationship (Cohen et al., 2006).  Clinically, one of 
the disadvantages of ezetimibe is the individual 
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variation in responsiveness to this drug.  Studies 
are also going on to reveal a relationship between 
ezetimibe efficacy and NPC1-L1 genotype (Simon 
et al., 2005).  These lines of studies may in the 
future make it possible to treat patients with hyper-
lipidemia in an “order-made” fashion, depending 
on their genetic haplotype of NPC1-L1.  
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